Quetiapine Capsule 10mg (Fluoxetine Hydrochloride)

Adult dosage

Adults 1. Depression 1) Initial treatment: The initial dose is 20mg of fluoxetine hydrochloride orally once daily in the morning. In controlled clinical trials, doses of 20～80mg per day were administered. If no improvement is observed, an increase in dose may be considered after several weeks. Doses exceeding 20mg per day should be administered in 2 divided doses (morning and noon), and the maximum dose of 80mg per day should not be exceeded. The onset of an adequate antidepressant effect may be delayed until 4 weeks or longer after starting treatment. 2) Maintenance/continuation/extended treatment: There are no definitive data on how long patients should be treated with this medicine; however, psychopharmacologists recognize that acute symptoms of depression require drug treatment for several months or longer. It is not known whether the amount of antidepressant required to relieve symptoms is the same as that required to maintain or sustain stability. 2. Bulimia nervosa Administer 60mg of this medicine per day. The daily dose should not exceed 80mg. Measure electrolyte levels before starting treatment. 3. Obsessive-compulsive disorder Administer 20～60mg of this medicine per day. The daily dose should not exceed 80mg. 4. Premenstrual dysphoric disorder Administer 20mg of this medicine per day. After 6 months of treatment, reassess whether continued treatment is necessary. Patients with renal and/or hepatic impairment, patients receiving multiple medications, elderly patients, and patients with comorbid diseases: Administer a lower dose or reduce the frequency of administration. Adjust the dose as appropriate according to age and symptoms. Switching from MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat a psychiatric disorder and starting treatment with this medicine, allow an interval of at least 14 days. Conversely, at least 5 weeks must elapse after discontinuing this medicine before starting an MAO inhibitor to treat a psychiatric disorder. Other MAO inhibitors such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue should not start treatment with this medicine because of the increased risk of serotonin syndrome. For patients requiring treatment for a more urgent psychiatric condition, including hospitalization or other interventions, treatment should be considered. It may be necessary to urgently administer linezolid or intravenous methylene blue to a patient already receiving this medicine. If no alternative to linezolid or intravenous methylene blue is available and the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome in a particular patient, discontinue this medicine immediately and administer linezolid or intravenous methylene blue. Monitor the patient for symptoms of serotonin syndrome for 5 weeks after administering linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever occurs first. Treatment with this medicine may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with methylene blue administered by a non-intravenous route (oral tablets or local injection) or with intravenous doses of 1mg/kg or less is unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with such use.

This medication is primarily used to treat psychiatric disorders such as depression. It may increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults, so it must be administered with great caution in this age group. This medication should not be administered to patients with allergies to this drug or its additives, severe renal impairment, or those taking certain medications (MAO inhibitors). Patients with a history of seizures should take special care when using this medication, and if seizures occur or increase in frequency, treatment should be discontinued immediately. Patients with suicidal thoughts or unstable mental states require careful monitoring during the initial weeks after treatment starts. This medication can affect heart rhythm, so patients with heart disease or related risk factors should undergo an ECG before being administered. Patients with reduced liver or kidney function may need to have their dosage adjusted. Diabetic patients may be affected in their blood sugar control, so they should closely monitor their blood sugar levels and adjust their medication dosage if necessary. This medication may dilate pupils, so caution should be exercised in patients with high intraocular pressure or risk of glaucoma. Rarely, severe allergic reactions or skin rashes may occur, so if any abnormal symptoms appear, consult a doctor immediately. Common side effects during treatment include headaches, nausea, insomnia, fatigue, diarrhea. Abruptly stopping this medication can lead to withdrawal symptoms such as dizziness, sensory disturbances, sleep disorders, and anxiety, so the dosage should be gradually reduced according to a doctor's instructions. This medication can interact with other drugs, so be sure to inform the doctor of any medications being taken, and it is advisable to avoid alcohol consumption. Women who are pregnant or breastfeeding should consult a doctor before using this medication. It is preferable not to administer this medication to children and adolescents, as its safety and efficacy have not been sufficiently confirmed in this population. Elderly patients may respond differently to the medication, so closer monitoring is needed during administration. This medication should be kept out of reach of children and should not be transferred to other containers.

Headache, nausea, insomnia, fatigue, diarrhea, anaphylactic reactions, serum sickness, abnormal secretion of antidiuretic hormone, decreased appetite, hyponatremia, anxiety, nervousness, restlessness, tension, decreased libido, sleep disturbances, abnormal dreams, depersonalization, elevated mood, happy mood, thought disorders, abnormal libido, bruxism, hypomania, mania, hallucinations, agitation, panic attacks, suicidal thoughts and behaviors, confusion, attention deficit, dizziness, taste disturbances, hypersomnia, drowsiness, tremors, psychomotor hyperactivity, movement disorders, ataxia, balance disorders, tonic-clonic seizures, seizures, akathisia, Buccglosal syndrome, serotonin syndrome, memory impairment, blurred vision, mydriasis, palpitations, ventricular arrhythmias, QT prolongation, flushing, hypotension, vasculitis, vasodilation, yawning, dyspnea, pharyngitis, pulmonary-related events, nosebleeds, vomiting, dyspepsia, dry mouth, dysphagia, esophageal pain, gastrointestinal bleeding, specific hepatitis, rash, urticaria, pruritus, hyperhidrosis, alopecia, increased tendency to bruising, diaphoresis, angioedema, petechiae, phototoxic reactions, purpura, erythema multiforme, arthralgia, myoclonus, myalgia, frequent urination, dysuria, urinary retention, voiding disorders, gynecological bleeding, erectile dysfunction, ejaculation disorders, sexual dysfunction, galactorrhea, hyperprolactinemia, priapism, anxious mood, chills, fatigue, abnormal mood, feeling cold, feeling hot, mucosal bleeding, weight loss, abnormal liver function tests, fractures, withdrawal symptoms, dizziness, sensory disturbances, sleep disturbances, weakness, anxiety, tremors, headache, anaphylactic-like reactions, progressive systemic reactions, severe skin reactions, kidney, liver, or lung-related reactions, suicidal behavior, hostility, growth delay, delayed puberty development, Stevens-Johnson syndrome, changes in platelet function, abnormal bleeding, aplastic anemia, atrial fibrillation, cataracts, cerebrovascular accidents, cholestasis jaundice, movement disorders, eosinophilic pneumonia, epithelial necrosis, nodular erythema, exfoliative dermatitis, gynecomastia, cardiac arrest, liver failure, hyperprolactinemia, hypoglycemia, immune-related hemolytic anemia, renal failure, exacerbation of movement disorders, optic neuritis, pancreatitis, pancytopenia, pulmonary embolism, pulmonary hypertension, thrombocytopenia, thrombocytopenic purpura, ventricular tachycardia, vaginal bleeding, aggressive behavior

This medication should be stored in a tightly closed container to prevent exposure to air or moisture and at a temperature between 1 to 30 degrees Celsius. Proper storage will maintain the medication's efficacy and prevent deterioration.

Appearance

A capsule with green upper and lower parts, filled with white or grayish-white powder.

Package unit

30 capsules/bottle, 300 capsules/bottle